Wednesday, 26 August 2026European Markets

ALMUNDA PRO NV Stock Bearish Momentum With A 16% Slide In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of ALMUNDA PRO NV (AEX-Index: AMUND.AS) dropped by a staggering 16.25% in 5 sessions from €1.6 to €1.34 at 05:07 EST on Wednesday, after two consecutive sessions in a row of gains. AEX-Index is dropping 0.97% to €756.67, after two successive sessions in a row of losses.

ALMUNDA PRO NV's last close was €1.34, 16.25% below its 52-week high of €1.60.

About ALMUNDA PRO NV

Almunda Professionals N.V., a business and IT consultancy company, provides business services in the financial sector. It offers consultancy services in the areas of regulatory change, digital transformation, information security, and information services. The company was formerly known as Novisource N.V. and changed its name to Almunda Professionals N.V. in August 2021. Almunda Professionals N.V. was founded in 2001 and is based in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, ALMUNDA PRO NV has a trailing twelve months EPS of €0.02.

PE Ratio

ALMUNDA PRO NV has a trailing twelve months price to earnings ratio of 67. Meaning, the purchaser of the share is investing €67 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.17%.

More news about ALMUNDA PRO NV (AMUND.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com